Take­da part­ner Finch joins forces with Cresto­vo, leap­ing in­to a mid-stage mi­cro­bio­me study

About 6 months af­ter Take­da part­nered up with mi­cro­bio­me biotech Finch Ther­a­peu­tics on a pre­clin­i­cal pro­gram for IBD, the Somerville, MA-based com­pa­ny has struck a deal to merge with Cresto­vo and piv­ot to a mid-stage ther­a­py.

Back at the end of June, Cam­bridge, MA-based Cresto­vo launched a Phase II tri­al dubbed PRISM 3 for CP101, a mi­cro­bio­me pro­gram for Clostrid­i­um dif­fi­cile in­fec­tion, which Finch has al­so been tar­get­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.